BRIB.F Stock Overview
Engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Brii Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.13 |
| 52 Week High | HK$0.36 |
| 52 Week Low | HK$0.13 |
| Beta | 1.45 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRIB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -2.1% |
| 1Y | n/a | -8.7% | 21.3% |
Return vs Industry: Insufficient data to determine how BRIB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BRIB.F performed against the US Market.
Price Volatility
| BRIB.F volatility | |
|---|---|
| BRIB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BRIB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BRIB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 95 | Zhi Hong | www.briibio.com |
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease.
Brii Biosciences Limited Fundamentals Summary
| BRIB.F fundamental statistics | |
|---|---|
| Market cap | US$137.43m |
| Earnings (TTM) | -US$37.63m |
| Revenue (TTM) | US$5.44m |
25.3x
P/S Ratio-3.7x
P/E RatioIs BRIB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRIB.F income statement (TTM) | |
|---|---|
| Revenue | CN¥38.38m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥38.38m |
| Other Expenses | CN¥303.83m |
| Earnings | -CN¥265.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 100.00% |
| Net Profit Margin | -691.63% |
| Debt/Equity Ratio | 0% |
How did BRIB.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/05 13:57 |
| End of Day Share Price | 2024/07/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangbin Zhou | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Geoffrey Porges | Leerink Partners LLC |